STOCK TITAN

Cardio Diagnostics Holdings Inc - CDIO STOCK NEWS

Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.

Cardio Diagnostics Holdings Inc (CDIO) delivers AI-powered innovations in cardiovascular risk assessment through its proprietary Genetic-Epigenetic Engine. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's advancements in precision diagnostics.

Access timely announcements about clinical validations, strategic partnerships, and regulatory developments shaping the future of preventive cardiovascular care. Our curated collection includes earnings reports, technology milestones, and peer-reviewed research insights directly impacting CDIO's market position.

Key updates cover advancements in AI-driven diagnostic accuracy, intellectual property expansions, and collaborations with medical institutions. Users gain critical insights into how CDIO's epigenetic analyses are transforming personalized healthcare approaches globally.

Bookmark this page for structured access to verified corporate communications and analysis of CDIO's growing influence in biotechnology. Regularly updated content supports informed tracking of the company's progress in redefining cardiovascular disease prevention through cutting-edge diagnostic solutions.

Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) announced the publication of a groundbreaking study in the Journal of the American Heart Association (JAHA) detailing the development and validation of PrecisionCHD, an artificial intelligence-guided integrated genetic-epigenetic test for detecting coronary heart disease (CHD). The test, a blood-based alternative to invasive and costly traditional methods, uses AI and personalized genetic and epigenetic information to sensitively detect CHD. The study, conducted in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics, involved 2,516 individuals and marks a significant leap in CHD diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
123.23%
Tags
none
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. and Family Medicine Specialists announce a partnership to implement advanced blood-based tests to identify patients at risk for coronary heart disease (CHD) events, aiming to prevent heart attacks and reduce treatment costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
102.94%
Tags
none
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc has received an Innovation Technology contract from Vizient, Inc. The contract allows Vizient's customer base, which includes over 60% of hospitals and 97% of academic medical centers in the US, to access Cardio Diagnostics' AI-driven molecular heart disease tests at negotiated pricing. The tests utilize a proprietary AI algorithm to analyze objective epigenetic and genetic biomarkers in patients suspected to be at risk or who may have coronary heart disease. This contract signifies recognition of Cardio Diagnostics' mission to transform cardiovascular disease management through advanced diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.78%
Tags
AI
Rhea-AI Summary
Cardio Diagnostics Holdings announces Supply and Distribution Agreement with Aimil Ltd to address the growing prevalence of heart disease in India.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc announces the launch of their new integrated facility in Iowa City, Iowa.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
none
-
Rhea-AI Summary
Cardio Diagnostics Holdings announces scalable framework for using AI-guided epigenetic assessments in CHD care
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.98%
Tags
none
Rhea-AI Summary
Cardio Diagnostics Holdings collaborates with Truckers Health Network to address heart disease among truckers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.65%
Tags
none
-
Rhea-AI Summary
Cardio Diagnostics Holdings announces AI-driven tests to be used in research study on coronary artery disease detection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.72%
Tags
partnership
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO) CEO to present at investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
conferences
Rhea-AI Summary
Cardio Diagnostics Holdings successfully completes employer-sponsored heart disease fair in Kansas, with over 75% employee participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
partnership conferences
Cardio Diagnostics Holdings Inc

Nasdaq:CDIO

CDIO Rankings

CDIO Stock Data

20.33M
48.21M
7.69%
4.93%
3.8%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
CHICAGO